Abbott sees ‘indicators of stability’ for 2023 as hospital staffing, provide chain improves

By the numbers


This autumn income: $10.1 billion

12% lower year-over-year


This autumn internet revenue: $1.03 billion

48.1% lower year-over-year


2022 income: $43.7 billion

1.3% improve year-over-year


2022 internet revenue: $6.93 billion

2% lower year-over-year

This autumn insights

Abbott Laboratories mentioned whereas it continues to face provide chain challenges, hospital staffing shortages and inflation, the corporate expects these pressures to ease in 2023. 

“Whereas these components stay headwinds, I am cautiously optimistic that we’re beginning to see them peak and in some instances ease a bit,” CEO Robert Ford mentioned in a Wednesday morning earnings name. 

Gross sales of the corporate’s COVID-19 assessments as soon as once more exceeded analyst estimates, whereas provide constraints and pandemic restrictions in China on the finish of the yr affected its medical machine enterprise.

The corporate’s vitamin enterprise was affected by the shutdown of a child system plant in Sturgis, Michigan, after system was recalled for bacterial contamination and the Meals and Drug Administration discovered unsanitary situations in an inspection. That plant is now the topic of a U.S. Division of Justice investigation. 

Within the fourth quarter, the corporate’s medical machine gross sales had been little modified from a yr earlier at $3.75 billion, whereas diagnostics income decreased 26% and vitamin gross sales fell 11%. 

“The working surroundings nonetheless stays difficult. Nevertheless it’s not as difficult as we noticed again in Q3 of 2022 in October,” Ford mentioned. “There are positively indicators right here of stability. There are indicators of enchancment, whether or not it is within the macroeconomic facet, or whether or not it is particularly within the segments that we’re competing in.”


Diabetes units had been Abbott’s largest and fastest-growing machine section by income, bringing in $1.27 billion within the fourth quarter. A lot of the complete, at $1.1 billion, was from gross sales of Abbott’s Freestyle Libre steady glucose displays. 

For the complete yr, Libre gross sales climbed greater than 21%, together with 42% development within the U.S. and within the mid-teens internationally, Ford mentioned. 

“Can we see a path for an additional 20% development in 2023? Yeah, I can,” Ford mentioned. 

He additionally talked concerning the growth of the CGMs to extra sufferers who use basal insulin solely as a “important alternative.” 

Ford expects that to start within the U.S., the place there are about 4 million sufferers with Sort 2 diabetes who take basal insulin, a couple of third of whom are lined by Medicare. The company has proposed new draft protection tips that will broaden entry to CGMs.

“I do not suppose it is a U.S.-only scenario. I believe that is going to begin to broaden internationally, given the medical information that you just see with Libre, and the influence that it has,” Ford mentioned. 

The corporate additionally will run a trial of a mixed glucose and ketone sensor, and put together for the launch of its Lingo platform, a brand new line of shopper wearables, beginning in Europe this yr. 


Though check gross sales declined by double digits within the quarter, they nonetheless outpaced analyst estimates, largely resulting from continued demand for speedy COVID assessments. 

Of the $3.3 billion in diagnostics income for the quarter, COVID-19 testing accounted for $1.07 billion. J.P. Morgan analyst Robbie Marcus wrote that quantity “got here in above our forecast for $514M, with speedy check gross sales of $1.02B driving the vast majority of this.” 

For all of 2022, the corporate’s diagnostics income elevated 6% year-over-year. 

“From a COVID perspective, in 2022 we truly offered extra assessments than then we offered in 2021,” Ford mentioned. 

Sooner or later, whereas Abbott expects COVID testing gross sales to say no “considerably,” they nonetheless will stay an vital a part of the enterprise, Ford mentioned.


Excluding COVID check gross sales, Abbott expects natural gross sales development within the high-single digits for 2023. 

“In the event you take [testing and recalls] out of the equation, you return to what we had been rising pre-pandemic, which was high-single digits, 7% to eight% development,” Ford mentioned. “That is what we grew in 2022, once more, excluding COVID and the influence of the recall merchandise.”

The corporate forecasts about $2 billion in income from COVID assessments for 2023 and expects diluted earnings per share of $3.05 to $3.25

Supply hyperlink

Related Posts